Research Article

Survival nomogram for patients with upper tract recurrence after resection for localized bladder urothelial carcinoma

Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China

^‡Authors contributed equally

Search for more papers by this author

Wanxiang Zheng^‡

Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China

^‡Authors contributed equally

Search for more papers by this author

Wei Zhang^‡

Department of Urology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, PR China

^‡Authors contributed equally

Search for more papers by this author

Yu Zheng

Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China

Search for more papers by this author

Lei Zhang

Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China

Search for more papers by this author

Ming Gao

Department of Andrology, Xi'an Daxing Hospital, Shaanxi University of Chinese Medicine, Xi'an, 710016, PR China

Assisted Reproduction Center, Northwest Women's & Children's Hospital, Xi'an, 710061, PR China

Search for more papers by this author

Fei Yan

Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China

Search for more papers by this author

Di Wei

Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China

Search for more papers by this author

Fuli Wang

Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China

Search for more papers by this author

Jianlin Yuan

*Author for correspondence: Tel.: +86 029 8477 5321;

E-mail Address: jianliny@fmmu.edu.cn

https://orcid.org/0000-0001-9166-3528

Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China

Search for more papers by this author

Published Online:5 Sep 2020https://doi.org/10.2217/fon-2020-0560

View article

Abstract

Aim: To develop a survival nomogram for patients with upper tract recurrence (UTR) after resection for localized bladder urothelial carcinoma (BUC). Methods: The data of 361 patients with UTR after resection for BUC registered in the Surveillance, Epidemiology, and End Results database were retrospectively analyzed. The nomogram was established using the Fine and Gray method and its predictive accuracy was assessed using the concordance index. The nomogram was calibrated by comparing the predicted and actual survival. Results: The concordance index of the nomogram was 0.746 (95% CI: 0.733–0.759). Excellent agreement was observed between the predicted and actual survival in all calibration plots. Conclusion: This study describes the first survival nomogram for patients experienced UTR after resection for BUC.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Yuan H, Chen X, Liu L et al. Risk factors for intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis. Urol. Oncol. 32(7), 989–1002 (2014).
MedlineGoogle Scholar
2. Su X, Fang D, Li X et al. The influence of tumor size on oncologic outcomes for patients with upper tract urothelial carcinoma after radical nephroureterectomy. Biomed. Res. Int. 2016, 4368943 (2016).
MedlineGoogle Scholar
3. Habuchi T, Takahashi R, Yamada H et al. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 342(8879), 1087–1088 (1993).
Medline CASGoogle Scholar
4. Jones TD, Wang M, Eble JN et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin. Cancer Res. 11(18), 6512–6519 (2005).
Medline CASGoogle Scholar
5. Krambeck AE, Thompson RH, Lohse CM et al. Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma. J. Urol. 177(5), 1721–1726 (2007).
MedlineGoogle Scholar
6. Cambier S, Sylvester RJ, Collette L et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance Bacillus Calmette-Guerin. Eur. Urol. 69(1), 60–69 (2016).
MedlineGoogle Scholar
7. Aziz A, Shariat SF, Roghmann F et al. Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making. BJU Int. 117(2), 272–279 (2016).
MedlineGoogle Scholar
8. Simone G, Bianchi M, Giannarelli D et al. Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy. World J. Urol. 33(10), 1419–1428 (2015). • The authors created nomograms able to predict disease-free and cancer-specific survival after radical cystectomy for urothelial carcinoma of the bladder by prospective data acquisition for the first time.
MedlineGoogle Scholar
9. Seisen T, Colin P, Hupertan V et al. Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. BJU Int. 114(5), 733–740 (2014).
MedlineGoogle Scholar
10. Roupret M, Hupertan V, Seisen T et al. Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J. Urol. 189(5), 1662–1669 (2013).
MedlineGoogle Scholar
11. Cha EK, Shariat SF, Kormaksson M et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur. Urol. 61(4), 818–825 (2012).
MedlineGoogle Scholar
12. Wheat JC, Weizer AZ, Wolf JJ et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urol. Oncol. 30(3), 252–258 (2012).
MedlineGoogle Scholar
13. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 69(1), 7–34 (2019).
MedlineGoogle Scholar
14. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics. 16, 1141–1154 (1988).
Google Scholar
15. Harrell FJ, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15(4), 361–387 (1996).
MedlineGoogle Scholar
16. Naser-Tavakolian A, Ghodoussipour S, Djaladat H. Upper urinary tract recurrence following bladder cancer therapy: a review of surveillance and management. Curr. Opin. Urol. 29(3), 189–197 (2019).
MedlineGoogle Scholar
17. Picozzi S, Ricci C, Gaeta M et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J. Urol. 188(6), 2046–2054 (2012).
MedlineGoogle Scholar
18. Golabek T, Palou J, Rodriguez O et al. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guerin immunotherapy? World J. Urol. 35(2), 237–243 (2017).
MedlineGoogle Scholar
19. Golabesk T, Palou J, Rodriguez O et al. Long-term bladder and upper urinary tract follow-up recurrence and progression rates of G1-2 non-muscle-invasive urothelial carcinoma of the bladder. Urology 100, 145–150 (2017).
MedlineGoogle Scholar
20. Yap SA, Schupp CW, Chamie K, Evans CP, Koppie TM. Effect of age on transitional cell carcinoma of the upper urinary tract: presentation, treatment, and outcomes. Urology 78(1), 87–92 (2011).
MedlineGoogle Scholar
21. Shariat SF, Godoy G, Lotan Y et al. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. BJU Int. 105(12), 1672–1677 (2010).
MedlineGoogle Scholar
22. Chromecki TF, Ehdaie B, Novara G et al. Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. World J. Urol. 29(4), 473–480 (2011).
MedlineGoogle Scholar
23. Roupret M, Babjuk M, Comperat E et al. European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur. Urol. 68(5), 868–879 (2015).
MedlineGoogle Scholar
24. Hou G, Zheng Y, Zhang L et al. Development and validation of a prognostic nomogram for patients with intravesical recurrence after radical nephroureterectomy for non-metastatic upper tract urothelial carcinoma. World J. Urol. 38, 1969–1975 (2020). •• This Surveillance, Epidemiology and End Results (SEER)-based study developed the first nomogram to predict prognosis in patients with intravesical recurrence after treatment for upper tract urothelial carcinoma.
MedlineGoogle Scholar
25. Azemar MD, Comperat E, Richard F, Cussenot O, Roupret M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol. Oncol. 29(2), 130–136 (2011).
MedlineGoogle Scholar
26. Yates DR, Hupertan V, Colin P et al. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. Br. J. Cancer 106(6), 1083–1088 (2012).
Medline CASGoogle Scholar
27. Jeldres C, Sun M, Lughezzani G et al. Highly predictive survival nomogram after upper urinary tract urothelial carcinoma. Cancer 116(16), 3774–3784 (2010).
MedlineGoogle Scholar
28. Ku JH, Moon KC, Jung JH, Jeong SH, Kwak C, Kim HH. External validation of an online nomogram in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. Br. J. Cancer 109(5), 1130–1136 (2013).
Medline CASGoogle Scholar
29. Mbeutcha A, Roupret M, Kamat AM et al. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J. Urol. 35(3), 337–353 (2017).
Medline CASGoogle Scholar
30. Hou G, Li X, Zheng Y et al. Construction and validation of a novel prognostic nomogram for patients with sarcomatoid renal cell carcinoma: a SEER-based study. Int. J. Clin. Oncol. 25(7), 1356–1363 (2020). •• This SEER-based study constructed the first external-validated nomogram for patients with sarcomatoid renal cell carcinoma.
MedlineGoogle Scholar
31. Liu J, Jin J, Yang Y et al. Prognostic impact of ALDH1 expression in transitional cell carcinoma of the renal pelvis. Anticancer Res. 35(9), 4829–4836 (2015).
Medline CASGoogle Scholar
32. Simone G, Papalia R, Loreto A et al. Independent prognostic value of tumour diameter and tumour necrosis in upper urinary tract urothelial carcinoma. BJU Int. 103(8), 1052–1057 (2009).
MedlineGoogle Scholar

Vol. 16, No. 34

Metrics

Downloaded 73 times

History

Received 30 May 2020

Accepted 24 July 2020

Published online 5 September 2020

Published in print December 2020

Information

Keywords

Author contributions

J Yuan, G Hou, W Zheng, L Zhang and F Wang developed the study design, carried out statistical analysis and wrote the first draft of the manuscript. W Zhang, Y Zheng, M Gao, G Hou, F Yan and D Wei collected the statistics and prepared the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors thank the SEER database.

Financial & competing interests disclosure

This work was supported by the Boost Program Research Project of Xijing Hospital (no. XJZT13Z05). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

All procedures performed in this study were in accordance with the 1964 Helsinki declaration and its relevant amendments. Because bladder urothelial carcinoma and upper tract urothelial carcinoma are diseases recorded in each US state and the data of patients registered in the SEER database are anonymized, ethical approval and informed consent from patients were not required.

Data sharing statement

The authors certify that this article reports the secondary analysis of clinical trial data that have been shared with them and that the use of this shared data is in accordance with the terms (if any) agreed upon receipt. The authors were permitted Internet access to the database (username: 10646-Nov2018) after a signed data use agreement was approved by the SEER administration (http://seer.cancer.gov/data/sample-dua.html).

Availability of data & materials

The datasets used and/or analyzed during the current study are available from the SEER database (http://seer.cancer.gov/data/sample-dua.html).

PDF download